ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Tolvaptan

Also written as “OPC-41061”, “tolvaptan” and “Tolvaptan MR”.

Its studies are mostly in Polycystic Kidney, Autosomal Dominant · Hyponatremia · Heart Failure · Fibrosis · Kidney Failure, Chronic, led by 2 companies.

Drug pageTolvaptan: every studyAll 89 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 15, 201155 company-led studies, 1 open or runningNext primary completion: Dec 28, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only541 open or runningphase 4since Sep 15, 2011Aug 13, 2002Dec 28, 2028phase 3 · NCT04782258
Jiangsu HengRui Medicine10 open or runningphase 3since Jan 5, 2012Jan 5, 2012none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Jiangsu HengRui Medicine only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 5, 2012First study: phase 3 study in HyponatremiaFirst studyNCT01507727 · 240 enrolled · China

TargetBeta

AVPR2 →read by rule
“An orally bioavailable, selective, arginine vasopressin receptor 2 (V2, AVPR2) antagonist that can be used to treat hyponatremia”NCIt, by rule
“Vasopressin V2 receptor antagonist”ChEMBL 37, by rule

Studies

The one study Jiangsu HengRui Medicine leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01507727Hyponatremia · China3UNKNOWNSep 2012240

How it is read

Names in the registry

  • “Tolvaptan”, 30 entries
  • “OPC-41061”, 12 entries
  • “tolvaptan”, 6 entries
  • “Tolvaptan MR”, 5 entries
  • “OPC-41061(Tolvaptan)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.